U.S. markets closed

Beximco Pharmaceuticals Limited (BXP.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
86.500.00 (0.00%)
At close: 4:25PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close86.50
Open87.40
Bid85.00 x 0
Ask88.00 x 0
Day's Range85.03 - 87.40
52 Week Range0.86 - 110.00
Volume114,277
Avg. Volume55,944
Market Cap690.613M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.01 (1.49%)
Ex-Dividend DateNov 23, 2020
1y Target Est84.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Serum Institute of India delays vaccines for private sale in Bangladesh; focus on state campaigns
      Reuters

      Serum Institute of India delays vaccines for private sale in Bangladesh; focus on state campaigns

      Beximco is Bangladesh's exclusive distributor of the Oxford University-AstraZeneca shot that SII, the world's biggest vaccine manufacturer, is producing in bulk for low- and medium-income countries. The Bangladeshi company last week received 5 million of the 30 million doses it had ordered from SII for Bangladesh's immunisation programme that begins next week. Beximco had separately ordered 1 million doses for sale on the private market, with the hope to start marketing it this month.

    • Bangladesh's Beximco signs COVID-19 vaccine deal with India's Serum Institute
      Reuters

      Bangladesh's Beximco signs COVID-19 vaccine deal with India's Serum Institute

      Bangladesh's Beximco Pharmaceuticals <BXPH.DH> is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday. The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus. SII has partnered with AstraZeneca <AZN.L>, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply.